Recombinant GBD-SSTad-SSTad protein and its preparation method and use

By developing a method for binding of recombinant protein GBD-SSTad-SSTad protein to dextran, the high cost and poor effect of existing SST antagonist analog treatments have been solved, and effective reduction of SST concentration and inducing specific antibodies have been achieved. Improves the effectiveness and economicality of infertility treatment.

CN114981296BActive Publication Date: 2024-12-03YOUSI PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080090554.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-12-25
Filing Date
2020-12-02
Publication Date
2024-12-03
Estimated Expiration
2040-12-02

AI Technical Summary

Technical Problem

The existing treatment methods for SST antagonist analogs require long-term systemic use of expensive drugs, and it is difficult to effectively reduce SST concentrations in animals' blood, limiting its scope of application, and traditional methods are difficult to effectively induce specific autoantibodies against SST. Influencing the treatment effect.

Method used

A recombinant protein GBD-SSTad-SSTad protein was developed to combine with dextran adsorbent through cell extracts from the E. coli BL21 [pGBD-SSTad-SSTad] strain to isolate and purify the desired product to form an injectable immunogen Sex compositions used to induce specific autoantibodies against SST and reduce the biological activity of SST.

Benefits of technology

This method can effectively increase the number of mature follicles and improve sperm quality, and is used to treat infertility, and by inducing autoantibodies to neutralize SST activity for a long time, it improves the durability and economicality of the treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003714932980000181
    Figure BDA0003714932980000181
  • Figure BDA0003714932980000191
    Figure BDA0003714932980000191
  • Figure BDA0003714932980000201
    Figure BDA0003714932980000201
Patent Text Reader

Abstract

The present invention relates to recombinant GBD-SSTad-SSTad protein and a method for preparing it on glucan. The present invention also relates to an immunogenic composition and a kit comprising the peptide. The present invention also relates to the use of the obtained protein in increasing the number of mature follicles and improving sperm quality. This technical achievement of increasing the number of mature follicles and improving sperm quality is based on the use of the KNFFWKTFTS peptide, which is part of a recombinant protein capable of inducing somatostatin autoantibodies. Therefore, the present invention can be used to treat male and female infertility. In addition, the protein of the present invention is immunologically active and easy to purify. The present invention is achieved by obtaining a recombinant protein comprising two antigenic determinants of somatostatin and a glucan binding domain. The implementation of the present invention also lies in an injectable preparation based on the specific protein, including subcutaneous or intramuscular injection of the preparation, which solves the problem of enhancing folliculogenesis and spermatogenesis in mammals, birds and humans.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to genetic engineering, biotechnology, immunology, and microbiology. Specifically, the present invention relates to a recombinant protein GBD-SSTad-SSTad and a method for producing the protein on glucan, comprising binding the protein GBD-SSTad-SSTad in a cell extract of the Escherichia coli BL21 [pGBD-SSTad-SSTad] strain to an α-glycan-containing adsorbent based on affinity interactions during incubation, followed by washing and separation of the desired product from unbound bacterial proteins. The present invention also relates to immunogenic compositions and kits containing the peptide. The present invention also relates to the use of the obtained protein in increasing the number of mature follicles and improving sperm quality. This technical achievement of increasing the number of mature follicles and improving sperm quality is based on the use of the KNFFWKTFTS peptide, which is part of a recombinant protein capable of inducing somatostatin autoantibodies. Therefore, the present invention can be used to treat male and female infertility. Background Art

[0002] In humans, folliculogenesis begins when some resting follicles leave the ovarian reserve and enter the growth phase. The activation of resting follicles remains a less studied process; however, modern literature data indicate that there are a series of related factors that regulate the dynamics of the balance of the numerous factors that activate and inhibit follicle development. Regulation of the molecular mechanisms responsible for controlling the activation of resting follicles may have important clinical applications in the process of mobilizing resting follicles in patients with infertility caused by ovarian dysfunction. Recently, somatostatin (which has a systemic inhibitory effect on the hypothalamic-pituitary-ovarian system) has attracted increasing interest from experts (Gougeon et al., 2010, Endocrinology. 151(3): 1299-309).

[0003] The mechanisms regulating the initiation of follicular growth remain poorly understood. Kit ligand (KL) was the first protein discovered to trigger follicular growth. This was based on analysis of the ovarian phenotype of animals carrying a spontaneously inactivating KL mutation (Huang et al., 1993, Dev. Biol, 157:100-109) and experimental studies (Yoshida et al., 1997, Dev. Biol. 184:122-137; Parrott et al., 1999; Endocrinology 140:4262-4271). In contrast, the peptide hormone somatostatin (SST) has an inhibitory effect on the initiation of follicular growth. SST has a strong inhibitory effect on multiple hormones (growth hormone, thyroid-stimulating hormone, insulin, glucagon, gastrin, pepsin), initiating inhibition of gastric, pancreatic, and intestinal enzyme secretion, slowing gastrointestinal motility and the excretion of its contents. There is evidence that the hypothalamic-pituitary-ovarian system is also a target of SST (Gougeon et al., 2010, Endocrinology 151(3):1299-309).

[0004] SST is a cyclic U-shaped peptide that exists in two forms in the body (SST-14, which contains 14 amino acids, and SST-28, which contains 28 amino acids). The biological activity of these two forms of SST is the same. SST-14 is predominant in the central nervous system and can inhibit the secretion of growth hormone by somatotropin-producing cells in the anterior pituitary gland. SST-28 is mainly found in the stomach and pancreas. The biological activity of SST is mediated by several membrane receptors that bind to protein G, of which five subtypes have been characterized, namely SSTR1-SSTR5 subtypes (Reubi, 1987, Cancer Res. 47:551-558; Resine et al., 1995, Endocrin Reviews 16:427-442; Lamberts et al., 1991, Endocrin Reviews 12:450-482).

[0005] SST has been reported to be present in the ovaries of several mammals, including pigs (Mori et al., 1984, Acta Endocrinol. (Copenh.) 106(2):254-259), rats (McNeill et al., 1987, Am. J. A. Nat. 179(3):269-76), and humans (Hoist et al., 1994, Hum. Reprod. 9(8):1448-1451). SST receptors, particularly subtypes 1, 2A, and 5 (Strauss et al., 2003, Hum Reprod 18(1):495-507), have been identified in rat ovaries (Lidor et al., 1998, Gynecol. Endocrinol. 12(2):97-101) and human ovaries. Therefore, it is reasonable to conclude that the ovaries of all mammalian species contain SST and its receptors. Another data provided in a previous patent suggests the presence of SST and its receptors in bird ovaries (RU 2337708, RU 2526571, Kudryavets NI, 2018, Gorki BGSKhA, Biological characteristics of birds of different species).

[0006] Experimental evidence suggests that SST may play a role in maintaining follicles in a resting state. SST is a peptide with well-known effects in endocrine tissues: it inhibits the formation of cAMP (Ben-Shlomo et al., 2007, IDrugs. 10(12):885-95) and also inhibits the production of KL by Sertoli cells (similar to granulosa cells) in boar testes. In rats, when SST is administered in vivo, the number of preovulatory follicles is reduced (Nestorovic et al., 2004, Gen Physiol Biophvs. 23(3):375-80), and in vitro SST inhibits the production of aromatase and progesterone by granulosa cells stimulated by FSH (Andreani et al., 1995, Hum Reprod. 10(8):1968-73). In porcine ovarian granulosa cells, SST inhibits cAMP production stimulated by luteinizing hormone (LH) and forskolin (Rajkumar et al., 1992 J Endocrinol. 134(2):297-306) and can inhibit nuclear maturation of perivascular oocytes.

[0007] SST also plays a key role in controlling male germ cell proliferation. The SST receptors (SSTRs) SSTR3, SSTR4, and SSTR5 are abundantly expressed in normal human testicular tissue, while SSTR1 and SSTR2 are typically absent. In rat testes, SSTR1, SSTR2, and SSTR3 receptors are primarily present in spermatocytes. Furthermore, SSTR1-3 mRNA is strongly accumulated in round spermatids from stages I to VII, with a sharp decrease at stage IX, when round spermatids begin to undergo transformation. All of this suggests that SST and its receptors are directly involved in mammalian spermatogenesis. Previous patent data suggests that SST and its receptors are involved in spermatogenesis in birds (RU 2337708, RU 2526571, Kudryavets NI, 2018, Gorki BGSKhA, Biological characteristics of birds of different species).

[0008] These findings strongly suggest that SST is a factor that maintains the quiescent phase of follicles and spermatids. SST can limit KL production by inhibiting cAMP production in granulosa cells. Therefore, SSTR antagonists or antibodies that bind to and neutralize SST activity could stimulate the transformation of growing follicles and spermatids.

[0009] The first of the above methods has been adopted in several studies and patents by A. Gougeon et al. (Gougeon, 2011, Gynecol Obstet Fertil. 39(9):511-3; Gougeon et al., 2010, Endocrinology 151(3):1299-309; Gougeon and Loumaye, EP 20040791488 08.10.2004; Gougeon, US20070155659 A1 5.7.2007; Tranand and Gotteland, EP 2835136 A111.02.2015), which describe the use of SST antagonist analogs in the preparation of a drug aimed at accelerating the onset of growth of resting follicles. The authors have developed SST antagonist analogs, which are cyclic or acyclic polypeptides that have high affinity for SST receptors and inhibit the functional activity of SST14 or SST28, such as inhibiting the secretion of growth hormone from pituitary somatotropin cells and / or inhibiting the proliferation of pituitary adenoma cells in vitro. Most SST antagonist analogs have high affinity for all or at least 2 or 3 SST receptor subtypes, or have a higher affinity for at least one of subtypes 1, 2, 3, 4 and 5 (e.g., subtype 2). The term "SST agonist analog" in published patents describes compounds that have an effective dose of 1 μM or less for at least one somatostatin receptor subtype DE50. In neonatal rat ovaries, SST receptor antagonists reduce the percentage of primordial follicles and increase the percentage of primary and secondary follicles (Gougeon et al., 2010, Endocrinology. 151(3):1299-309).

[0010] Gougeon (US 20070155659 A15.7.2007) discovered that SST and its analogs can influence the transition of follicles from the resting phase to the growing phase. The authors have demonstrated the use of SST or SST agonist analogs in the preparation of a medicament for reducing or inhibiting the growth of resting follicles. Conversely, the use of SST antagonist analogs accelerated the onset of growth of resting follicles. Thus, for the first time, it has been demonstrated that, by using modified SST derivatives, it is possible to directly influence follicle growth, accelerating or slowing follicular development. For each mouse, one ovary was incubated in culture medium (control), while the other ovary was incubated in the presence of SST, KL, or the SST antagonist BIM-23627. The ovaries were then histologically evaluated for the content of primordial follicles, primary follicles, and secondary follicles. The results showed that KL and BIM-23627 reduced the percentage of primordial follicles and increased the percentage of primary and secondary follicles compared to ovaries from control mice.

[0011] The inventors intend to use SST antagonist analogs for in vitro or in vivo fertilization of animals with high market value. In particular, such animals may include horses, ruminants, sheep or goats; they may also include transgenic animals. The inventors have found that the main advantage of the technology developed is the preparation of drugs based on SST antagonist analogs to activate dormant follicles in the animal's ovarian reserve and initiate the growth phase. Administration of such drugs to animals for 1-12 months can increase the number of growing follicles, which can be stimulated to reach the pre-ovulatory follicular phase using standard treatment regimens. Similar data were also obtained in the patent of Tran and Gotteland (EP2835136 A1 11.02.2015).

[0012] Similar results were observed in rhesus monkeys after the use of the SST antagonist PGL1001 (Ting et al., 2019, J Assist. Reprod. Genet. 36(2):229-239). Systemic administration of PGL1001 did not affect the animals' overall health, menstrual cycle duration, or cyclical ovarian hormone levels compared to the control group. PGL1001 treatment increased ovarian circumference and oocyte fertilization rate compared to the same parameters in the control group of animals receiving a placebo.

[0013] However, the proposed technology has many limitations in its use because it requires the systemic administration of expensive SST antagonist derivatives for many months. By using not only antagonist analogs but also techniques that neutralize SST activity with autoantibodies, it is possible to reduce SST concentrations in animal blood and reduce binding to receptors in the hypothalamic-pituitary-ovarian system.

[0014] In addition to protective functions, the body's immune system also performs regulatory functions related to cell proliferation and other genetically determined functions of its own cells by producing specific autoantibodies against the body's biologically active compounds (Poletaev AB et al., 2002, Medicine: 168-172). In contrast to antigens, autoantigens are components of self-proteins, protein complexes, or body cells that are partially heterologous under the influence of various damaging factors and infectious agents or due to the deliberate destruction of natural immune tolerance. In this case, it is achieved by administering specially formulated endogenous antigens. Reverse immunomodulation can induce the production of these antibodies. The reverse immunomodulation method is based on inducing autoantibodies to endogenous biologically active compounds, which are carried out by introducing endogenous biologically active compounds in the form of covalent conjugates with carrier antigens, thereby permanently and purposefully changing the physiological functions in the body. The term was proposed by IP Ashmarin (Ashmarin et al., 1989, Bull Exp Biol Med 12: 695-697). In foreign literature, the term "autoantigenicity" is used to describe the disease in question (Poletaev et al., 2012, Pathophysiology 19(3):221-31).

[0015] Antibodies against endogenous bioactive compounds (especially hormones) can bind to the corresponding compounds and reduce their concentration and bioactivity ( 2003, Autoimmunity 36:183-189). This results in a smooth change in many physiological and biochemical processes, with which hormone regulatory factors are directly or indirectly involved. In this case, molecules containing the entire SST or any fragment of SST act as immunogens (autoantigens that induce an immune response), causing the body to produce antibodies against this endogenous factor. These antibodies will bind to endogenous SST, thus becoming autoantibodies, thereby reducing its concentration in the blood, thereby preventing it from interacting with specific receptors and weakening its physiological effects on the body.

[0016] More than 30 years ago, independent research groups in the United States, Canada, the United Kingdom, and Russia conducted experiments on active immunization of animals (cattle, sheep, and pigs) with somatostatin-14 (Spencer, 1984, JR Soc Med. 77(6):496-500). The authors of the study noted that, under the same maintenance conditions, the immunized animals showed a 15-20% excess weight gain compared to the control animals, and thus an increase in endogenous somatostatin levels was found in the blood. Subsequently, experiments were conducted on different types of animals. Active immunization of animals with a protein obtained by covalently conjugating synthetic SST to a carrier protein resulted in increased levels of growth hormone (Spencer et al., 1986, Comp Biochem Physiol A Comp Physiol. 85(3):553-6), insulin growth factor (Dubreuil et al., 1991, Domest Anim Endocrinol. 8(2):307-21), gastrin (Westbrook et al., 1998, Am J Physiol. 274(4):751-6), and other bioactive compounds related to somatostatin. Active anti-somatostatin immunization resulted in an 8-17% increase in body weight.

[0017] Somatostatin immunoneutralization avoids many of the disadvantages associated with the use of anabolic or recombinant growth hormones. The mechanism of action of somatostatin immunoneutralization is based on the temporary binding of specific antibodies to endogenous SST and the increase in endogenous growth hormone concentrations within physiological limits in animals. However, due to the high cost, the long-term and widespread use of active animal immunization against endogenous SST-14 is impossible, as the main method for producing peptides is chemical synthesis, which economically limits the implementation of this method in practice. The small size of SST-14 does not allow direct microbial synthesis using recombinant DNA technology. Several methods have been described for the synthesis of SST-14 in the form of chimeric proteins, followed by isolation of the desired product, but none have provided satisfactory results (Itakura et al., 1977, Science 198(4321):1056-63; Nespovitaya et al., 2014, Protein Expr Purif. 99:78-86; Maicas et al., 2013, Mol Biotechnol. 55(2):150-158).

[0018] Patent RU 2031121 CT of Lunin VG et al. develops an injectable preparation for increasing meat and milk productivity in farm animals and poultry, which is based on a chimeric protein comprising a water-insoluble enzymatically active chloramphenicol acetyltransferase (Sat) without the 10 C-terminal amino acids, an amino acid spacer, and SST-14 having the amino acid sequence AGCKNFFWKTFTSC (Som) in an oil solution containing additives.

[0019] Lunin VG et al. have been granted patent RU 2561467, entitled "A method of production of preparation to increase meat and milk productivity of farm animals (options) and preparation produced by method". Yudin SM et al. found that the previously developed preparation Sat-Som based on recombinant SST also improved fertility and helped increase sperm production in male farm animals, roosters and humans (patent application RU (11) 2493873 (13) C1 Yudin SM et al., "Injectable preparation for increasing sperm production in stud livestock and roosters and method for use thereof"; Russian Federation invention patent No. 2526571, Yudin SM and Yudina TI, "Injectable preparation for increasing human sperm production and method for use thereof"). Both inventions aim to improve the body's reproductive capacity, increase the amount of ejaculated sperm, and improve some quality parameters of sperm. The injectable preparation is intended for use in physiologically mature males, farm animals, and humans, at a dose of 50-200 μg of the chimeric Sat-Som protein per 1 kg of live weight. The present invention allows for improved sperm production: by using an injectable preparation, the amount of ejaculated sperm is increased and sperm waste in terms of biological indicators is reduced in breeding stock, roosters, and humans. Subsequent studies conducted by the applicant showed that immunization of female rats with a somatostatin-containing Sat-Som drug resulted in an increase in the size of the animals' ovaries, as well as an increase in the size of primary and secondary follicles (Yudin SM et al., 2017; Effect of somatostatin-containing preparation on folliculogenesis. Issues of gynecology, obstetrics and perinatology. 16(2):26-33).

[0020] However, the purification technology used for the somatostatin-containing protein Sat-Som in question did not completely remove some bacterial proteins, lipopolysaccharides, and DNA from the production strain, which does not meet modern quality biotechnology standards for immunobiological preparations. The formation of the correct native U-shaped structure of SST and the formation of the cysteine ​​bridge between cysteines 3 and 14 is also a challenging task ( Figure 1 ).

[0021] To overcome this technical limitation, we developed a novel recombinant protein containing somatostatin, which consists of a glucan-binding domain (GBD), a separating spacer (sp), and two truncated SST variants with the sequence KNFFWKTFTS, termed the antigenic determinant of somatostatin (SSTad): GBD-sp-SSTad-sp-SSTad.

[0022] A peptide with the sequence KNFFWKTFTS is described in U.S. Patent No. 4,261,885. However, this document mentions the inhibition of pituitary adenoma cell proliferation. Therefore, the expert could not find an obvious connection between the specific peptide and the purpose of use of the present invention, as well as the technical results obtained by implementing the present invention. As mentioned above, the small size of somatostatin-14 constitutes a challenging problem in microbial synthesis, which prevented the authors from looking for ways to develop its synthesis method, which is related to the significant reduction in the size of the peptide. It should be assumed that it is the specified 10-amino acid somatostatin fragment that has shown itself to be an effective means of increasing folliculogenesis and spermatogenesis in mammals, birds and humans.

[0023] Unlike the method developed by Geugeon et al., which requires systemic use of expensive SST antagonist analog derivatives for several months, the technology of the present invention allows reducing the concentration of SST in the blood of animals and reducing the binding of SST to the receptor after two or three immunizations with preparations containing recombinant somatostatin proteins, thereby achieving optimal neutralizing titers of autoantibodies.

[0024] The object of the present invention is to develop a method for stimulating folliculogenesis and spermatogenesis in humans, mammals, animals and birds with a composition containing immunogenic somatostatin by binding to endogenous SST, increasing the activity of sex hormones in serum and inducing complex rearrangements of adaptive forms, which manifests as structural transformation of the organs of the reproductive system and is intended to stimulate the reproductive potential of mammals, birds and humans, by using an injectable formulation that meets the requirements of pharmaceutical analysis and uses an approved adjuvant that allows injection without unpleasant pain.

[0025] Based on this goal, the present invention aims to develop a recombinant, immunologically active somatostatin-containing protein that is easily purified and sufficiently immunogenic against SST as an antigen. This protein can be used to stimulate folliculogenesis and spermatogenesis in mammals, birds, and humans by inducing the synthesis of specific autoantibodies against SST, thereby blocking its activity. Another object of the present invention is to formulate a formulation based on this protein and to develop a method for using this formulation that overcomes the problem of developing anti-SST autoantibodies in vivo after systemic administration of this formulation, leading to increased sex hormone concentrations and folliculogenesis and spermatogenesis activity in mammals, birds, and humans. It is important to note that the amino acid sequence of SST is identical in humans and all mammals and birds. Therefore, the developed formulation is a universal drug for enhancing folliculogenesis and spermatogenesis in humans, mammals, and birds.

[0026] The advantage of this approach is that a drug based on the SST autoantigen can be developed to accelerate the onset of growth of resting follicles. On average, one in six married couples attempting to conceive have difficulty conceiving. While there are many reasons for this high prevalence, two treatment options, known as "medically assisted childbirth," have been developed and are commonly used to treat human infertility. These aim to induce the simultaneous growth of multiple preovulatory follicles, known as "medically assisted delivery." This allows for the production of several mature oocytes and, consequently, embryos, increasing the chances of pregnancy. This can be achieved by administering one or more drugs that stimulate the pituitary gland to secrete the gonadotropins FSH (follicle-stimulating hormone) and LH, such as antiestrogens (e.g., clomiphene or tamoxifen) or aromatase inhibitors (e.g., letrozole, anastrozole, or exemestane). Alternatively, human FSH preparations (extracts or recombinant forms) with or without LH can be administered to induce the simultaneous growth of several preovulatory follicles. Once the follicles reach preovulatory size, one of two treatment options (types) is chosen, depending on the cause of infertility. The first is intrauterine insemination (IUI). The second involves retrieving oocytes from the ovaries by aspirating follicles (5-15 oocytes) and fertilizing them in the laboratory (in vitro fertilization), either by simply incubating the oocytes with the partner's sperm (IVF) or by direct sperm microinjection into the oocytes (ICSI). To optimize the success rate (pregnancy rate) of this treatment, obtaining several mature oocytes is crucial; however, in some women, despite adequate ovarian stimulation, the number of oocytes retrieved is low or even just one. Adverse reactions to stimulatory therapy are due to the limited number of growing follicles present in these patients' ovaries. Therefore, the ability to activate the ovarian reserve follicles and force them into the growth phase is a clear therapeutic advantage. The advantage of this approach lies primarily in the ability to use SST autoantigens to treat female infertility.

[0027] Another object of the present invention is the use of SST autoantigens in the preparation of a medicament for accelerating the growth of resting ovarian follicles in premenopausal females and spermatocytes in males. Administration of such a medicament can increase the number of growing follicles in females (which can be stimulated to the preovulatory follicular phase via standard therapy) and increase sperm counts in males. In the early 20th century, a concentration of 60 to 100 million sperm per ml of ejaculatory duct was considered normal (Macomber and Sanders, 1929, N Engl J. Med. 200:981). However, the lower limit of sperm concentration in the ejaculatory duct (which typically distinguishes normozoospermia from oligozoospermia) has steadily decreased, initially to 40 million / ml and then to 20 million / ml (MacLeod and Gold, 1951, J. Urol. 66:436-442). According to the most recent WHO recommendations from 2010, a concentration of 15 million sperm per ml of semen is considered normal. The reasons for the persistent decline in spermatogenic activity are unknown, and according to the WHO 2010 criteria for germ cell production (World Health Organization Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction, Cambridge: Cambridge University Press, 2010), there is an urgent need to stimulate it in pathology, and even in normal circumstances.

[0028] According to the present invention, pharmaceutical formulations containing SST antigenic determinants can be administered parenterally (subcutaneously, intramuscularly, intraperitoneally, intravenously) or transdermally. The subcutaneous route is preferred because it allows for delivery of effective concentrations of the active ingredient to dendritic cells and macrophages. A dosage form is prepared based on the SST antigenic determinant used in a composition consisting of a recombinant protein with an acceptable adjuvant and necessary excipients, so that each route of administration is effective and repeatable.

[0029] The dosage of the preparation of the present invention for treating the above-mentioned diseases or conditions and the number of inoculations can vary according to the route of administration, the age and weight of the patient and the patient's condition. The final decision on the treatment plan is made by a doctor or veterinarian, respectively.

[0030] According to the results of the present invention, the applicant has discovered that it is possible to inhibit the SST receptor response by inducing the synthesis of specific autoantibodies against SST antigenic determinants. This results in a pharmacological effect on the ovarian reserve, i.e., the onset of quiescent follicle development is accelerated compared to similar parameters in control animals, resulting in a decrease in the percentage of primordial follicles, an increase in the percentage of primary and secondary follicles, and an increase in spermatogenesis in mammals, birds and humans. Summary of the Invention

[0031] The present invention provides a novel use of a peptide antigenic determinant of somatostatin KNFFWKTFTS and its analogs as part of a fusion recombinant protein, which can accelerate folliculogenesis and spermatogenesis in mammals, birds and humans.

[0032] On the one hand, the present invention relates to a recombinant GBD-SSTad-SSTad protein with a molecular weight of 39.5 kDa, wherein the recombinant GBD-SSTad-SSTad protein comprises two SST protein fragments with a sequence of SEQ ID NO: 1, a Gly-Ser spacer with a sequence of SEQ ID NO: 2 or SEQ ID NO: 3, and an α-glucan binding domain from a gene of Streptococcus mutans with a sequence of SEQ ID NO: 4, and the recombinant protein is encoded by the GBD-SSTad-SSTad gene with a nucleotide sequence of SEQ ID NO: 5.

[0033] In a second aspect, the present invention relates to a method for preparing recombinant GBD-SSTad-SSTad protein on glucan, the method comprising: during incubation, based on affinity interaction, binding the GBD-SSTad-SSTad protein in the cell extract of Escherichia coli BL21[pGBD-SSTad-SSTad] strain to an adsorbent containing α-glycan, and then washing and separating the desired product from unbound bacterial proteins.

[0034] In a third aspect, the present invention relates to a pharmaceutical composition, which is an injectable preparation for enhancing folliculogenesis and spermatogenesis in mammals, birds and humans, comprising a recombinant GBD-SSTad-SSTad protein and an adjuvant suitable for injection.

[0035] In a fourth aspect, the present invention provides a method for enhancing folliculogenesis and spermatogenesis in mammals, birds and humans by subcutaneous or intramuscular injection of a preparation containing recombinant GBD-SSTad-SSTad protein at a dose of 5-200 μg of the protein per kilogram of body weight of the mammal or bird.

[0036] Furthermore, the present invention may relate to a pharmaceutical pack or kit comprising one or more containers containing a recombinant protein of the present invention comprising the antigenic determinant of somatostatin KNFFWKTFTS as part of a recombinant fusion protein. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 The cysteine ​​bridge between cysteines at positions 3 and 14 is shown.

[0038] Figure 2 The U-shaped structure of somatostatin is shown. DETAILED DESCRIPTION

[0039] The present invention relates to a compound comprising an antigenic determinant of somatostatin KNFFWKTFTS as part of a fusion recombinant protein to accelerate the growth of resting follicles, folliculogenesis and the initiation of spermatogenesis in mammals, birds and humans for the treatment and prevention of infertility.

[0040] In a preferred embodiment, the present invention relates to a compound comprising the somatostatin KNFFWKTFTS antigenic determinant as part of a fusion recombinant protein, which, when the active ingredient of the compound is administered to a mammal, bird or human, accelerates the growth of resting follicles, folliculogenesis and the onset of spermatogenesis in mammals, birds and humans for the treatment and prevention of infertility.

[0041] In a more preferred embodiment, the present invention relates to compounds comprising the antigenic determinant of somatostatin KNFFWKTFTS as part of a fusion recombinant protein to accelerate the growth of resting follicles, folliculogenesis and the initiation of spermatogenesis in mammals, birds and humans undergoing assisted reproductive therapy for the treatment and prevention of infertility.

[0042] The present invention provides immunogenic compositions of compounds comprising antigenic determinants of somatostatin KNFFWKTFTS and its analogs, and methods for treating infertility in patients (mammals, birds and humans) in need thereof.

[0043] In one embodiment, the present invention provides novel polypeptides and polynucleotides encoding novel polypeptides, including SSTad polypeptides fused to carrier proteins via functionally optimized spacers. The fusion polypeptides of the present invention provide highly effective and inexpensive materials for treating infertility. The carrier protein (GBD) plays a special role in the present invention that is not disclosed in the above-mentioned analogs, performing multiple functions: a carrier protein for protecting low molecular weight SSTad from protease attack, an affinity domain for purifying the fusion protein on a polysaccharide adsorbent, and an immobilization domain on a high molecular weight polysaccharide for enhancing the antigen and increasing its immunogenicity.

[0044] The spacer sequences used were optimized in length and composition to ensure efficient expression of the SSTad fused to the carrier protein in various microorganisms, particularly Escherichia coli. The new spacer sequences enhance protease resistance and optimize the SSTad's effect on the patient's immune system. They promote the formation of the natural U-shaped structure of the SSTad (SST between two cysteines) and expose it to the exterior of the fusion protein, thereby forming an immunodominant epitope.

[0045] In another embodiment, the present invention provides novel adjuvant compositions for treating infertility patients. In one specific application, the SSTad compound can be combined with the novel adjuvant and used to treat or prevent diseases or conditions of infertility or oocyte deficiency, such as sperm deficiency in males. The adjuvants herein are intended to be optimized for use in mammals, animals, birds, and particularly humans. The adjuvants herein enhance the immunogenicity of the antigen, allowing for a lower amount of antigen to be included in the vaccine and achieving higher titers of SST-specific antibodies.

[0046] In another embodiment of the present invention, a pharmacological composition is provided that produces immunogenicity against SSTad, which initiates the production of specific antibodies, the binding of antibodies to SST, and the reduction of its content in the blood. This eliminates the inhibitory effect of SST on follicular release and maturation and spermatogenesis. The vaccine formulation scheme in the present invention is optimized for safety and the desired effect of achieving high immunogenicity of the SSTad construct in a safe and highly effective adjuvant formulation. The vaccine of the present invention requires a lower amount of antigen (compared to the antigen concentration in traditional subunit vaccines), has an extended shelf life and is relatively low in cost.

[0047] The present invention focuses on the treatment of infertility in humans and other vertebrates, including mammals and birds, in which it is desired to restore the number of mature ovarian follicles and the quality of sperm.

[0048] The following definitions are provided herein to facilitate understanding of certain terms frequently used in the present invention, but are not intended to limit the scope of the present disclosure.

[0049] definition

[0050] "Patient" refers to a vertebrate, warm-blooded animal, typically a mammal or bird, in need of the compositions and / or methods of the present invention, such as a human (female) in need of restoring or increasing the number of mature oocytes, or a human (male) in need of restoring or increasing sperm production and quality.

[0051] "Treatment" refers to an improvement in a patient's condition compared to an untreated patient under relatively identical circumstances or at the starting point of treatment. Treatment generally indicates that the desired pharmacological and / or physiological effect has been achieved using the compositions and methods of use of the present invention. Treatment can include prophylactic use of the results of the present invention.

[0052] As used herein, the term "infertility treatment" refers to the treatment of a disease or condition related to the health of the female reproductive system, selected from the group consisting of: ovarian failure, premature ovarian failure, infertility, anovulation, infertility characterized by "ovarian hyporesponsiveness" to gonadotropin therapy, delayed puberty, infertility associated with elevated FSH levels, previous treatment with IVF and ART (assisted reproductive technology), spontaneous premature ovarian failure (early menopause), polycystic ovary disease (few growing follicles), and hyporesponsiveness (poor response) to COS (controlled ovarian stimulation).

[0053] The term "infertility treatment" also refers to the treatment of disorders related to male reproductive health selected from substantial infertility associated with subnormal sperm density and motility, secretory disorders, primary or secondary failure of spermatogenesis.

[0054] The terms "ovarian reserve" or "ovarian follicular reserve" are used to describe the number of primary follicles remaining in the ovaries.

[0055] The term "quiescent primordial follicles" is used to describe dormant or primordial follicles in the ovarian reserve. The present invention also relates to compositions and / or methods of use provided herein to accelerate maturation of follicles from the ovarian reserve in the treatment of infertility.

[0056] The "primary follicle (awakening)" is a round structure in the mammalian ovary, consisting of a primary oocyte surrounded by a zona pellucida, several layers of cuboidal follicular cells, and connective tissue. The primary follicle is 3 to 4 times larger than the primordial follicle.

[0057] The secondary follicle is ten times larger than the primordial follicle. A follicular fluid cavity, up to 2.5 centimeters in diameter, forms around the oocyte. The follicular cells themselves form a complex two-layered structure.

[0058] "Amino acid" refers to any of the twenty naturally occurring proteinogenic amino acids, as well as any modified amino acids.

[0059] "Protein" and "peptide" are used to refer to an amino acid polymer, a group of two or more interacting amino acid polymers, or a linked amino acid polymer.

[0060] An "antigenic determinant" or "epitope" is a portion of an antigenic macromolecule that is recognized by the immune system (antibodies, B lymphocytes, T lymphocytes). The portion of an antibody that recognizes an epitope is called a paratope. While an epitope usually refers to a molecule that is foreign to a given organism (proteins, glycoproteins, polysaccharides, etc.), the region of a molecule itself that is recognized by the immune system is also called an epitope. Epitopes recognized by antibodies or B cells are mostly three-dimensional structures on the surface of antigenic molecules (conformational epitopes), whose charge and hydrogen bond shapes and spatial arrangement are exactly the same as those of the corresponding antibody paratopes.

[0061] "Isolation" refers to the separation or recovery of a polynucleotide or polypeptide from at least degradation products of the producer strain's cells. Purification of the polypeptide from contaminating cellular components and polypeptides can be accomplished using any of a number of well-known methods, including precipitation with ammonium sulfate or ethanol, anion or cation exchange chromatography, hydrophobic interaction chromatography, and affinity chromatography.

[0062] An "antibody" refers to a Y-shaped molecule with a pair of antigen-binding sites, a hinge region, and a constant region.

[0063] "Vaccine" refers to any composition capable of stimulating the immune system of a vaccinated subject to produce antibodies against SST for the purposes described herein.

[0064] Somatostatin

[0065] SST is a peptide hormone that, among other things, inhibits the release of growth hormone from the anterior pituitary. SST regulates various endocrine functions by interacting with G-protein-coupled SST receptors on target endocrine cells. SST is secreted by the hypothalamus, stomach, intestines, and pancreas. Controlling SST levels in patients is important for improving productivity, altering feeding behavior, and increasing folliculogenesis and spermatogenesis in mammals and birds. This invention describes the effects of SST on the reproductive system.

[0066] In studies, SST vaccination has been shown to optimize the productivity of mammals. Overall, farm animals immunized with SST experienced an 8-17% increase in weight, a 9% decrease in appetite, and an 11% increase in food efficiency. Animals immunized with SST and their offspring had the same correct proportions of muscle, bone, and fat as control animals and the same animal weight distribution (Reichlin, 1987, Lab Clin Med. 109(3):320-326). Therefore, these studies suggest that inducing autoimmunity against SST in target animals can provide safe and effective results.

[0067] SST is known to inhibit a number of hormones involved in growth, animal absorption of food, and reproductive regulation. As previously described in U.S. Patent No. 6,316,004 and U.S. Patent Application Serial No. 12 / 195979, SST and SST fusion variants can be used to immunize animals to increase daily weight gain and, if necessary, milk production. These immunization procedures are performed using traditional adjuvants. SST immunization has also been used to treat endogenous growth hormone deficiency (Haffer, EP 2291194 B1). SSTad immunization has not previously been used to treat infertility.

[0068] The present inventors have obtained unexpected and reproducible results demonstrating that modified SST antigens, immunogenic compositions and vaccines comprising SSTads can be used to treat diseases or improve physiological conditions in patients, in particular to treat and prevent infertility.

[0069] advantage

[0070] Embodiments of the present invention provide SSTad-based methods for treating and preventing infertility in vertebrates, particularly mammals and birds. Exemplary embodiments of the present invention relate to treating humans, mammals and birds. The vaccine of the present invention (see below) is administered to humans, other mammals and birds to limit or inhibit the effects of endogenous SST on the reproductive system. The vaccine of the present invention will result in additional folliculogenesis and spermatogenesis. Vaccines comprising SSTad and adjuvants are optimized for use in vertebrates, particularly for treating human diseases that cause infertility. Because SST is a highly conserved hormone in vertebrates, embodiments of the present invention can elicit an immune response in all target vertebrates vaccinated using the methods and compositions described herein. A significant advantage of the present invention is that in vaccinated patients, booster immunizations may take weeks to months, which allows the patient's immune system to bind to SST, reduce its concentration and / or clear it from the body for a long time.

[0071] The technical aspects of the present invention facilitate all stages of SSTad vaccine production and use, providing simple and efficient techniques for obtaining SSTad entities and producing highly immunogenic compositions for the prevention and treatment of infertility. This immunogenic SSTad compound is optimized for expression in production cells, purification techniques, and formation of the native SST conformation, as well as formulation of immunogenic compositions.

[0072] In all variants of the genetically engineered construct, SSTad is expressed in the form of a codon-optimized chimeric carrier protein, a spacer, and SSTad. The carrier protein, due to its combination with a polysaccharide adsorbent, provides a simple and effective technology for purification from other bacterial proteins, lipopolysaccharides, and DNA of the production strain. The antigen based on the SSTad of the present invention, due to the combination of the carrier protein with a high molecular weight soluble polysaccharide, provides the formation of a molecular complex of larger size (20-40 nm), thereby providing immunogenicity and resistance to protease degradation. Therefore, the SSTad of the present invention exists in the patient's tissue for a longer time in the form of an immunogenic composition, and has a greater impact on the patient's immune system. As described in more detail below, due to the optimized adjuvant, the present invention also provides a maximized immune response.

[0073] New vaccine options for infertility treatment

[0074] There are two active forms of somatostatin, somatostatin-28 and somatostatin-14, which are produced by selective hydrolysis of the precursor peptide. However, the amino acid sequence of the fourteen peptides that bind to the SST receptor is the shorter peptide KNFFWKTFTS (SEQ ID NO: 1), NFFWKTFT, FFWKTF and FWKT, which has been confirmed by many synthetic SST analogs (Heidarpour et al., 2019, J Res Med Sci. 26: 24-29). FWKT is the key sequence required for specific receptor binding. Therefore, FWKT is the minimum key epitope for antibodies to neutralize the interaction between SST and the receptor. However, using recombinant protein technology, it is difficult to reproduce the U-shaped conformation of this short peptide ( Figure 2 ).

[0075] The KNFFWKTFTS sequence is highly conserved among vertebrates (Lin et al., Comp. 1998, Biochem. Physiol. C. Pharmacol. Toxicol. Endocrinol. 119(3):375-388) and, as shown in the present invention, is optimal for mounting a specific immune response.

[0076] The polysaccharide binding domain can be linked to the SSTad via a spacer of variable length. The spacer is necessary to ensure optimal presentation of the encoded somatostatin to the patient's immune system on the surface of the protein molecule. The spacer variants used in the present invention provide efficient formation of the U-shaped SST conformation, increased protease resistance, and optimal action on the epitope, and have demonstrated unexpected additional improvements over constructs lacking a spacer sequence and / or comprising a spacer sequence different from that provided herein.

[0077] The length and composition of the spacer variants have been optimized to ensure that the SSTad fused to the carrier protein is efficiently expressed in a variety of microorganisms (especially Escherichia coli). As mentioned above, these new spacer sequences provide enhanced protease resistance (therefore providing enhanced antibodies compared to the construct disclosed in U.S. Patent 6,316,004) and the best effect on the patient's immune system. Compared with using Sat-Som immunity, the SSTad combination connected using the spacer of the optimized configuration and the polysaccharide binding domain shows unexpected improvement in the immunity of the target patient to increase folliculogenesis and spermatogenesis. These constructs are intended to be used as antigens comprising SSTad when treating infertility.

[0078] The above-mentioned SSTad recombinant fusion protein exhibits high storage stability. In addition, considering the increased resistance of these materials to degradation, the SSTad-based antigens of the present invention provide deposition function and longer half-life in patients. It is worth noting that other carrier polypeptides can replace the polysaccharide binding domain and be linked to the SSTad. For example, the SSTad can be conjugated to KLH, tetanus toxoid, CRM 197, chloramphenicol acetyltransferase, or other protein carriers.

[0079] Embodiments of the present invention also provide novel adjuvant compositions for enhancing humoral immune induction in target patients. Compared with traditional (aluminum hydroxide, oil), these adjuvant compositions provide significant improvements in inducing humoral responses and are safe for humans, mammals, and birds. Adjuvant compositions are used herein together with SSTad-based antigens to prepare vaccines of the present invention.

[0080] In one embodiment of the present invention, the immunoadjuvant comprises dextran-500 to bind to the carrier protein and form a large-sized (20-40 nm) high-molecular-weight polysaccharide soluble molecular complex, providing immunogenicity and resistance to protease degradation. DEAE-dextran-500 binds to CpG oligonucleotides and provides them with resistance to nuclease degradation. In more detail, the complex is prepared using animal CpG oligonucleotide 1585 and human CpG oligonucleotide 2216. The CpG oligonucleotide is prepared by oligonucleotide synthesis. In some embodiments of the present invention, monophosphoryl lipid A, muramyl dipeptide, polymuramil or other ligands of toll-like receptors can be used, but CpG oligonucleotides are more preferably used in the treatment of infertility. Immunogenic compositions that do not contain CpG oligonucleotides can be used, but to achieve comparable results in the treatment of infertility, significantly larger amounts of SSTad fusion protein and longer immunization schedules will be required. The CpG oligonucleotide is dissolved in saline. The adjuvant composition was combined with the recombinant SSTad fusion protein to prepare the vaccine of the present invention (Example 5).

[0081] In another embodiment, the immunoadjuvant comprises Montanide TM (Examples 6, 7, 8) or aluminum hydroxide (Example 9). Adjuvants are combined with SSTad fusion polypeptides to prepare the vaccines of the present invention. The adjuvants used in the present invention are safe and effective for mammals, birds, and humans, and do not contain animal products and carcinogenic compounds.

[0082] The adjuvants and their concentrations used are detailed below.

[0083] Vectors and host cells

[0084] The present invention further relates to vectors containing polynucleotide molecules of the present invention, and host cells transformed with such vectors. Any polynucleotide molecule of the present invention can be connected to a vector that typically comprises a selectable marker and a replication site for the corresponding production cell. The production cell is genetically engineered to replicate these vectors to express a protein of the present invention. Typically, the vector in the embodiment provided comprises a polynucleotide molecule of the present invention that is operably connected to a suitable transcription or translation regulatory sequence, such as the sequence of a bacterial or viral host cell. Examples of regulatory sequences include transcription promoters, operators, mRNA ribosome binding sites, and corresponding sequences for controlling transcription and translation. When the regulatory sequence of the present invention was operably related to the polynucleotide encoding the fusion polypeptide of the present invention, the nucleotide sequence was operably connected.

[0085] Typical vectors include plasmids, yeast shuttle vectors, baculovirus, modified adenovirus, etc. In one embodiment, the vector is a modified pET30 plasmid. Host cells used in the present invention include bacteria such as Escherichia coli, yeast, SF-9 insect cells, mammalian cells, plants, etc.

[0086] In one embodiment, the regulatory sequence comprises a T7lac, Trp or T5 promoter for expressing the fusion protein of the present invention in E. coli or other prokaryotic cells. These regulatory sequences are widely reported and used under appropriate and varying conditions. Various plasmids of the present invention have been designed to express the fusion protein of the present invention using regulatory sequences. Plasmids containing the T7lac promoter are preferred.

[0087] Host cells for expressing target fusion proteins include prokaryotes, yeasts and higher eukaryotic cells. Exemplary prokaryotic hosts include cells from the bacteria of Escherichia, Salmonella and Bacillus and Pseudomonas and Streptomyces. In an exemplary embodiment, the host cell belongs to Escherichia and can be Escherichia coli (E.coli). As shown in the examples below, constructs of the present invention provide the best expression of SSTad, which is coupled at intervals with the polysaccharide binding domain under various conditions. These constructs are particularly effective in the expression in prokaryotic host cells, particularly in the bacteria of Escherichia.

[0088] In one embodiment, the pET plasmid containing the SSTad fusion protein gene is used to transform the E. coli cells, which has a regulatory sequence suitable for expression in E. coli cells. In some cases, the fermentation of approximately 10 liters of these cells produces at least 100 grams of total biomass, which then produces approximately 10 grams of total protein. By staining with silver and Coomassie blue, one-quarter of the protein mass is the target protein.

[0089] Purification of GBD-SSTad-SSTad fusion protein

[0090] The fusion protein can be purified according to conventional protein purification techniques, including, for example, lysis of bacterial cells with the enzyme lysozyme, disruption of DNA using ultrasound or deoxyribonuclease in French-press modules, followed by differential centrifugation of inclusion bodies, solubilization of inclusion bodies in guanidine chloride or urea, refolding, column chromatography on affinity and ion exchange columns, etc.

[0091] Aspects of the present invention include preparing immunogenic fusion proteins that are free of endotoxin. In some embodiments, the fusion protein is prepared in a state that is substantially free of endotoxin. According to pharmacopoeia standards, additional purification can completely remove endotoxin or reduce endotoxin concentration to a level acceptable to humans. Therefore, some embodiments of the technology disclosed herein allow for the preparation of fusion proteins that are substantially free of endotoxin for use in vaccines. In some embodiments, the endotoxin level is equal to or lower than 1EU / ml, while in other embodiments, endotoxin is removed, that is, the fusion protein of the present invention is substantially free of endotoxin.

[0092] The concentration of the purified fusion protein ranges from 1 to 8 mg / ml, typically 4 to 6 mg / ml. In some cases, the dose of the substantially endotoxin-free chimeric protein used in the vaccine composition is about (1.5 to 5 mg) / 2 ml, more typically, (2.0 to 3.5 mg) / 2 ml.

[0093] vaccine

[0094] The vaccines of the present invention are combinations of an immunoadjuvant as described herein and an antigen necessary to prevent or treat conditions associated with infertility in patients.

[0095] The pharmaceutical dosage of one embodiment of the vaccine used herein comprises 1-5 mg of the recombinant fusion protein. In all embodiments, the vaccine must be sterile and stable under the conditions of manufacture and storage. Microbial growth can be prevented by adding various antibacterial and antifungal agents, such as benzyl alcohol, parabens, chlorobutanol, sorbic acid, thimerosal, and the like.

[0096] The adjuvants of the present invention are combined with SSTad fusion polypeptides to provide vaccines for treating diseases and / or conditions associated with infertility.

[0097] The vaccine of the present invention generally comprises the SSTad antigen at a recombinant protein dosage of 1 mg / ml to 10 mg / ml.

[0098] Dextran 500 at doses of 1mg / ml to 10mg / ml,

[0099] DEAE-dextran 500 at doses from 0.2mg / ml to 2mg / ml,

[0100] 0.02 mg / ml to 0.2 mg / ml of monophosphoryl lipid A, muramyl dipeptide and / or CpG oligonucleotide 1585.

[0101] The vaccine solution of the present invention is prepared by mixing the raw materials (antigens, adjuvants, other ingredients) in the required amounts and volumes and performing terminal sterilization using ultrafiltration. Alternatively, the vaccine solution of the present invention can be prepared using individually sterilized components prior to final formulation.

[0102] The vaccine of the present invention can be prepared in the form of a sterile lyophilized formulation comprising CpG (Example 5), Montanide TM Oil emulsion (Examples 6, 7, 8) or aluminum hydroxide suspension (Example 9). These formulations are stable under production and storage conditions. Embodiments of the vaccine according to the present invention may further comprise a dispersant or wetting agent, a suspending agent or other similar raw materials.

[0103] Methods of treating patients' diseases

[0104] The present invention provides a pharmaceutical-grade vaccine comprising the SSTad fusion protein of the present invention and an adjuvant. Such a vaccine can be used for infertility patients.

[0105] The vaccine of the present invention is intended to treat infertile patients. In one embodiment, the vaccine of the present invention is applied twice, however, the number of injections can be increased to 3-5 times at the discretion of a medical professional or veterinarian. A typical dose of the vaccine antigen is 50-100 μg / ml of fusion recombinant protein per kilogram of patient body weight. The vaccine can be administered by conventional methods. In one embodiment, the vaccine is administered by subcutaneous injection (Examples 5, 6, 7, 8). In another embodiment, the vaccine is administered by intramuscular injection (Example 9).

[0106] The progress of treatment in patients receiving the vaccine formulations of the present invention should be monitored by providing additional dosing as necessary. Increased levels of growth hormone and anti-SST antibodies are target indicators for monitoring treatment efficacy. Based on individual patient observations, additional vaccine injections can be administered according to the present invention using adjustable amounts of SST antigen. Furthermore, a medical professional or veterinarian may determine whether alternative adjuvant combinations may be used to modify a particular patient's response to vaccination.

[0107] The proposed treatment regimen can be combined with other conventional infertility treatments. For example, the vaccination contemplated by the present invention can be combined with conventional hormonal treatment strategies.

[0108] In general, the described invention can be evaluated more readily by reference to the following examples.

[0109] Example

[0110] The following means and methods are used to solve the problems of cloning, production and purification of recombinant GBD-SSTad-SSTad protein.

[0111] This 39.5 kDa recombinant protein consists of two somatostatin (SSTad) antigenic determinant fragments (SEQ ID NO: 1), a Gly-Ser spacer (SEQ ID NO: 2), a spacer (SEQ ID NO: 3) that facilitates the U-shaped conformation of SST, and an α-glucan binding domain (GBD) from a gene of Streptococcus mutans (SEQ ID NO: 4). This recombinant protein is encoded by the GBD-SSTad-SSTad gene (SEQ ID NO: 5).

[0112] A method for producing recombinant GBD-SSTad-SSTad protein on dextran, comprising:

[0113] - Cultivate E. coli cells to express the GBD-SSTad-SSTad gene;

[0114] - GBD-SSTad-SSTad protein in the cell extract composition of the E. coli strain BL21 binds to the dextran-containing adsorbent due to affinity interactions during the incubation process;

[0115] - The desired product is then washed and separated from unbound bacterial proteins.

[0116] The recombinant GBD-SSTad-SSTad protein includes the protein sequence of a glucan-binding domain, which determines the protein's ability to bind to glucan-containing adsorbents, thereby achieving one-step concentration, purification, and immobilization of the protein product on glucan. Immobilization on glucan is facilitated by the presence of a glucan-binding domain derived from the α-glucan-binding domain of a Streptococcus mutans gene in the recombinant protein. The described domain exhibits a high affinity for α-glucans (amylopectin, glycogen, dextran, starch) and forms irreversible binding to the support over a wide range of pH values ​​from 6.0 to 9.0 and salt concentrations from 0 to 3 M NaCl.

[0117] Because E. coli cells lack proteins that bind to α-glucan, the recombinant GBD-SSTad-SSTad protein synthesized in the cells is the only protein in the production strain that strongly binds to α-glucan. This provides a means for the one-step production of high-purity recombinant protein preparations immobilized on glucan-containing adsorbents.

[0118] An injectable formulation for enhancing folliculogenesis and spermatogenesis in mammals, birds, and humans, comprising a recombinant GBD-SSTad-SSTad protein as described above, suspended in a medium consisting of an adsorbent containing dextran in a liquid carrier suitable for injection. A method for increasing folliculogenesis and spermatogenesis in mammals, birds, and humans comprises administering a formulation containing the recombinant GBD-SSTad-SSTad protein suspended in a medium consisting of an adsorbent containing dextran in a liquid carrier suitable for injection, twice subcutaneously or intramuscularly, at intervals of 14 to 20 days, at a dose of 5 to 200 μg of the protein per kilogram of patient body weight.

[0119] Therefore, the provided bifunctional recombinant GBD-SSTad-SSTad protein is capable of spontaneously binding to a dextran-containing adsorbent to form a highly immunogenic composition in the form of multiple antigens to induce the synthesis of SST-specific autoantibodies when administered to a patient, thereby stimulating folliculogenesis and spermatogenesis.

[0120] Example 1. Preparation of recombinant GBD-SSTad-SSTad fusion protein

[0121] The first step is to obtain the somatostatin antigenic determinant gene and then clone it. The SSTad gene is obtained using a chemical-enzymatic method. An oligonucleotide duplex encoding the corresponding gene is obtained and optimized for expression in Escherichia coli. The GBD-SSTad-SSTad plasmid is then obtained, which contains sequences encoding somatostatin, a spacer, and a glucan binding domain (GBD).

[0122] Example 2. Preparation of Escherichia coli strains producing recombinant somatostatin antigen coupled to a glucan binding domain

[0123] To generate an E. coli strain producing the recombinant GBD-SSTad-SSTad protein, E. coli BL21 cells were transformed with the pGBD-SSTad-SSTad plasmid. 3 μl of 0.1 M isopropyl-β-O-thiogalactopyranoside (IPTG) solution was added to the culture, and the mixture was incubated at 37°C for 3 hours. When comparing the range of proteins synthesized by the E. coli BL21 [pGBD-SSTad-SSTad] strain, an additional protein band was identified. The molecular weight corresponding to the additional band was consistent with the expected molecular weight of 39.5 kDa for the recombinant GBD-SSTad-SSTad protein. The level of protein synthesis in E. coli was determined by comparing the staining intensity of the recombinant protein band with that of the corresponding protein standard molecular weight band. These results indicate that the recombinant GBD-SSTad-SSTad protein is synthesized in the E. coli cells as insoluble inclusion bodies.

[0124] Example 3. Obtaining recombinant GBD-SSTad-SSTad protein immobilized on α-glucan

[0125] To obtain the recombinant protein, a culture of E. coli BL21 [pGBD-SSTad-SSTad] cells was grown in 1000 ml of LB medium (Luria broth) containing ampicillin (100 μg / ml) at 37°C to an optical density corresponding to 1 absorbance unit at 550 nm. 15 μl of 0.1 M IPTG solution was added to the culture and incubated for 3 hours. The cells were pelleted by centrifugation at 5000 g for 15 minutes.

[0126] The pellet was resuspended in phosphate buffered saline (PBS) containing lysozyme. Furthermore, the suspension was sonicated. After centrifugation at 6000 g, insoluble GBD-SSTad-SSTad protein remained in the pellet. The pellet was suspended in 8 M urea and centrifuged at 12,000 g for 30 minutes, and the supernatant was collected. To immobilize the recombinant GBD-SSTad-SSTad protein on the adsorbent, the supernatant was diluted four-fold with phosphate buffered saline, 1 / 10 the volume of α-glucan suspension was added, and the mixture was incubated at 25°C for 2 hours. The mixture was centrifuged at 8000 g, and the pellet was resuspended in phosphate buffered saline; the mixture was washed three times with α-glucan. The GBD-SSTad-SSTad antigen immobilized on α-glucan was a suspension of the adsorbent, onto which the protein was adsorbed. The purity of the preparation was at least 95%. The preparation was preserved by adding benzyl alcohol to a final concentration of 0.1% (by volume).

[0127] Example 4. Biological effects of recombinant GBD-SSTad-SSTad protein

[0128] In a preferred embodiment of the present invention, the formulation comprises recombinant GBD-SSTad-SSTad protein, which is lyophilized together with necessary excipients and CpG oligonucleotides, or the recombinant GBD-SSTad-SSTad protein is suspended in Montanide TM The drug is administered in an aqueous oil suspension of 50% (by weight) or aluminum hydroxide, and the dosage is 5-200 μg of recombinant protein per kilogram of animal or bird body weight, administered twice subcutaneously or intramuscularly, 20 days apart. The mechanism of action of the drug is based on the temporary blocking of endogenous SST activity by autoantibodies.

[0129] The following examples illustrate the efficacy of the formulation in enhancing folliculogenesis and spermatogenesis in mammals, birds and humans.

[0130] Example 5.

[0131] In order to describe the in vivo effects of an injectable formulation with an SST antigenic determinant and determine its effect on primary follicle development, the patent applicant studied an in vivo mouse model. The close similarity of the reproductive system, particularly the similarity in ovarian morphology, physiology, and endocrinology between rodents and women, makes mice a useful model for studying ovarian function, fertility aneurysms, and ovarian reserve regulation (Dixon et al., 2014, J Toxicol Pathol, 27 (3-4 Suppl); Cora et al., 2015, Toxicol Pathol., 43 (6): 776-793). Based on the results of the above studies, the applicant unexpectedly found that by inducing the synthesis of specific autoantibodies against SST, it is possible to inhibit the response of the SST receptor, which leads to a pharmacological effect on the ovarian reserve of the ovary and thus accelerates the onset of resting follicle growth. This effect leads to an increase in the number of primary and secondary follicles compared to control animals.

[0132] Each animal was injected subcutaneously twice, 20 days apart, with 50 μg of recombinant protein each time to study the biological activity of the immunogenic composition. The lyophilized vaccine preparation was suspended in saline and injected subcutaneously.

[0133] Table 1 shows the results of the enzyme-linked immunosorbent assay (ELISA) of the blood in the form of antibody titers. In this case, the antibody titers in blood samples obtained from mice were compared after immunization with four vaccine compositions containing various adjuvants using recombinant GBD-SSTad-SSTad as the antigen. The vaccines differed in the presence or absence of molecular adjuvants, namely monophosphoryl lipid A, muramyl dipeptide and CpG oligonucleotide 1585. Each composition was assigned to a group of 5 mice. From the results obtained for each group, the mean value of the ELISA dilution parameter (titer) was derived. The highest value, equal to 6 × 10 4 The lowest value, equal to 2 × 10 3 Based on the data obtained, it can be concluded that the most significant immune response was elicited by the composition using CpG oligonucleotides as adjuvant.

[0134] Table 1. ELISA dilution parameters (antibody titer)

[0135]

[0136] GBD-SSTad-SSTad is a recombinant protein, dextran 500, DEAE is dextran 500, MPLA is monophosphatidylserine A, MDP is muramyl dipeptide, and CpG is an oligonucleotide.

[0137] Histological examination results

[0138] Despite differences in the values ​​of the ELISA dilution parameters when using compositions containing various adjuvants, the level of follicular response was approximately the same in all groups of mice studied.

[0139] Histological examination of the ovaries of mice immunized with GBD-SSTad-SSTad using a previously studied combination revealed a significant increase in the number of follicles in the vaccinated group, from 11.1 to 18.8, representing a 69% increase, compared to the mean value of the control group. This parameter includes the total number of all follicles: from primordial to follicles and Graaf's follicles, and is characterized by an increase in their differentiation rate, a result that can be considered a positive effect on folliculogenesis.

[0140] After vaccination, the total number of structural and functional elements also increased from a mean of 25.8 in the control group to a mean of 43.1 across all groups. This represents a 67% increase. In addition to follicles, this value also includes atretic elements and corpora lutea. The latter form during the luteal phase after oocyte release. Luteinization has been observed in unovulated follicles in rare cases, and this parameter can be interpreted as the number of mature oocytes released. The average number of corpora lutea in the control group was 8.2. In the experimental group, this number increased to 13.3 (a 62% increase), indicating that immunoneutralization of endogenous SST has a positive effect on increasing oocyte release during ovulation.

[0141] Atresia elements form at different stages of folliculogenesis, including those in follicles that have not yet reached the mature Graaf vesicle stage and those undergoing destructive changes. An increase in the number of these elements was also observed after immunoneutralization, from 6.5 in the control group to 11.0 in the experimental group (a 69% increase), consistent with the increase in follicles and a general increase in the number of structural and functional elements in the ovary.

[0142] Table 2. Morphological and functional evaluation of the effects of GBD-SSTad-SSTad formulation on the ovary

[0143]

[0144] Approximate values ​​for the studied parameters were obtained in works and patents using SST antagonist analogs (Gougeon, 2011, Gynecol Obstet Fertil. 39(9):511-3; Gougeon et al., 2010, Endocrinology 151(3):1299-309; Gougeon and Loumaye EP 20040791488 08.10.2004; Gougeon US 20070155659A15.7.2007; Tran and Gotteland EP2835136A1 11.02.2015).

[0145] Example 6.

[0146] To restore the sexual cycle and fertility of dairy cows with hypoovarian function, a GBD-SSTad-SSTad formulation was studied.

[0147] Postpartum ovarian dysfunction is one of the factors that hinders high-yielding dairy cows from maximizing their reproductive and production potential. Its primary manifestation is ovarian dysfunction, characterized by suppressed folliculogenesis and ovulation. Postpartum ovarian dysfunction refers to a hypothalamic-pituitary regulatory disorder associated with altered neuroendocrine system function.

[0148] The trial was conducted on 40 infertile dairy cows with clinically significant signs of ovarian hypofunction. In the animals, persistent lack of libido was observed (no return of sexual cycles within 2.5-3.0 months after parturition). Transrectal ultrasound examination showed reduced ovarian size with growing follicles measuring 6-10 mm in diameter.

[0149] The experiment was conducted on 40 dairy cows, divided into two groups of 20. The first group of animals was injected with GBD-SSTad-SSTad at a dose of 50 μg per kg live weight (see Example 3 for dosage selection for large animals). The recombinant GBD-SSTad-SSTad protein was injected subcutaneously twice, 20 days apart, in a suspension containing 50% α-glycan (by weight), a water-oil suspension of Montanide. TM A second group of individuals (untreated (intact)) were selected as controls and followed up for 3 months.

[0150] Within three months, fertility was restored in only 26.7% of the control cows, whereas it was restored in 85.7% of the animals that received the GBD-SSTad-SSTad protein formulation (Table 3). The duration of infertility per cow in the experiment was shortened by 1.8 times when GBD-SSTad-SSTad was used.

[0151] Table 3. Efficacy of preparations containing GBD-SSTad-SSTad protein on ovarian dysfunction in dairy cows

[0152]

[0153] Thus, when administered to cows with hypoovarian function, GBD-SSTad-SSTad acts specifically on the pituitary-gonadal system, alleviating postpartum ovarian disease characterized by suppression of folliculogenesis and ovulation.

[0154] Example 7.

[0155] The following examples demonstrate the efficacy of this formulation in enhancing spermatogenesis in physiologically mature breeding stock. To select the optimal dosage (dose selection), three groups of Large White boars were injected twice with the GBD-SSTad-SSTad formulation at doses of 25, 50, or 100 μg of recombinant protein per kg live weight, 20 days apart. The recombinant GBD-SSTad-SSTad protein was suspended in a mixture consisting of 50% by weight α-glycan, a water-oil suspension of Montanide. TM The drug was administered subcutaneously in a medium containing 50% (by weight) of the drug. Before and after administration, boar sperm was collected, and the sperm concentration in the ejaculatory duct and the number of semen doses were determined according to established procedures and ejaculated volume. Spermatogenesis parameters in boars at a dose of 25 μg / kg live weight are shown in Table 4. The drug has a positive effect on boar spermatogenesis.

[0156] Table 4. Sperm production parameters in Large White boars using a GBD-SSTad-SSTad formulation at a dose of 25 μg / 1 kg live weight of recombinant protein (n=5)

[0157]

[0158] According to the data presented in Table 4, at a dose of 25 μg of active ingredient per kilogram live weight, the GBD-SSTad-SSTad formulation resulted in a slight increase in spermatogenesis in Large White boars compared to baseline values. Ejaculate volume increased by 5.9-8.0%, depending on the timing of control (30, 60, or 90 days after the second injection of the drug). Ejaculate sperm concentration increased by 2.8-5.8%, resulting in a 15.4-16.7% increase in the number of semen doses received per animal.

[0159] Sperm production parameters in Large White boars using the GBD-SSTad-SSTad formulation at a dose of 50 μg recombinant protein per kg live weight are shown in Table 5.

[0160] As can be seen from the data presented in Table 5, administration of the GBD-SSTad-SSTad formulation at a dose of 50 μg of active ingredient per kg live weight resulted in a significant increase in spermatogenesis in Large White boars compared to baseline values. Depending on the time of control of this parameter (30, 60, and 90 days after the second injection of the drug), the animals' ejaculate volume increased by 13.9-20.0%.

[0161] Table 5. Sperm production parameters in Large White boars administered a GBD-SSTad-SSTad formulation at a dose of 50 μg recombinant protein per kg live weight (n=3)

[0162]

[0163]

[0164] The sperm concentration in the semen obtained from the animals increased by 13.2-15.0%, which resulted in a 26.8-35.6% increase in the number of semen doses obtained from one animal.

[0165] Sperm production parameters in Large White boars when the GBD-SSTad-SSTad formulation was administered at a dose of 100 μg recombinant protein per kg live weight are shown in Table 6.

[0166] According to the data presented in Table 6, administration of the GBD-SSTad-SSTad formulation to Large White boars at a dose of 100 μg of active ingredient (recombinant protein) per kg live weight resulted in spermatogenesis above baseline values. The animals experienced a statistically significant increase in ejaculated sperm volume, ranging from 14.8% to 19.3%, depending on the time of control for this parameter (30, 60, and 90 days after the second injection of the drug). The sperm concentration in the animals' semen increased by 8.3% to 10.7%, which resulted in a 21.5% to 33.0% increase in the number of semen doses received by a single animal.

[0167] Table 6. Sperm production parameters in Large White boars administered a GBD-SSTad-SSTad formulation at a dose of 100 μg recombinant protein per kg live weight (n=3)

[0168]

[0169] Thus, the experiments conducted under the conditions of an industrial pig farm to identify the most effective dose of the GBD-SSTad-SSTad formulation confirm its pharmacological activity and its prospective use for stimulating spermatogenesis in Large White boars.

[0170] Similar biological effects were observed when the two GBD-SSTad-SSTad formulations (50 and 100 μg per kg animal body weight) were used. Therefore, a dose equivalent to 50 μg / kg GBD-SSTad-SSTad is recommended.

[0171] Analysis of boar spermatograms showed increased spermatogenesis following administration of the formulation at a dose of 50 μg protein per kilogram live weight (Table 7). Throughout the observation period, boar ejaculate volume, sperm concentration, and motility increased, resulting in a statistically significant 25.2% increase in the number of semen doses suitable for insemination of sows and gilts compared to baseline values. In semen from experimental animals, a 10% increase in absolute sperm survival was observed after 60 days of administration of the GBD-SSTad-SSTad formulation compared to baseline values.

[0172] Table 7. Effect of GBD-SSTad-SSTad formulation on boar sperm production parameters when 50 μg of recombinant protein was administered per 1 kg of animal live weight (n=5)

[0173]

[0174] When sows were inseminated with semen from boars that had received the GBD-SSTad-SSTad formulation, the fertilizing ability of the sperm was found to be increased. In the group of sows inseminated with semen from boars that had received the formulation, there was a trend towards increased multiple pregnancies, with the number of live born piglets increasing by 10%.

[0175] Example 8.

[0176] The preparation containing the recombinant GBD-SSTad-SSTad protein was subcutaneously injected into dairy cows twice, 20 days apart, at a rate of 50 μg of recombinant protein per kg of animal live weight. The protein was suspended in a suspension consisting of α-glycan (50% by weight), Montanide, an aqueous oil suspension. TM The spermatogenesis parameters of the animals on days 30, 60 and 90 after the second injection of the preparation are shown in Table 8.

[0177] Table 8. Sperm production parameters in dairy cows when using the GBD-SSTad-SSTad formulation at a dose of 50 μg of recombinant protein per 1 kg of animal live weight (n=3)

[0178]

[0179] Results from the GBD-SSTad-SSTad formulation demonstrated a positive effect on sperm production and bovine sperm quality. In sires, ejaculate volume increased statistically by 12% during the observation period, the number of semen doses received per animal increased by 40%, and sperm rejection decreased by 2%. Sperm concentration in semen from dairy cows remained unchanged during the observation period.

[0180] Example 9.

[0181] The following examples illustrate the efficacy of the GBD-SSTad-SSTad formulation in enhancing spermatogenesis in physiologically mature roosters.

[0182] The effects of the formulation on the production quality of breeder chickens (a hybrid of Plymouth Rock and Cornish) were studied in a poultry farm.

[0183] This formulation consisted of a suspension of 50 μg / kg of recombinant GBD-SSTad-SSTad protein in a medium consisting of α-glycan and aluminum hydroxide suspension. The formulation was administered twice, 20 days apart, at a dose of 50 μg / kg live weight. Sperm samples were obtained from males before and after administration of the formulation, and ejaculate volume, sperm concentration, and the number of semen doses received were measured. Spermatogenesis parameters in males administered at a dose of 50 μg / kg live weight are shown in Table 9.

[0184] Table 9. Spermatogenesis parameters of roosters using GBD-SSTad-SSTad formulation at a dose of 50 μg / kg live weight (n=5)

[0185]

[0186] The experimental results confirmed the stimulating effect of the preparation on sperm production in male breeders. Consequently, 90 days after the first injection, ejaculated semen volume increased by 40%. During the observation period, sperm quality parameters improved, including sperm survival. The use of the GBD-SSTad-SSTad preparation in male breeders increased the number of semen doses received by 40% and reduced sperm rejection rates, as measured by biological parameters.

[0187] The above-described embodiments of the present invention are not restrictive. Other embodiments are also possible within the scope of the patent claims.

[0188] However, based on the studies carried out and attempts to implement the present invention, this example demonstrates that the main feature of the present invention is a new spacer that is specifically designed to solve the problem of effective vaccination with highly immunogenic proteins in the treatment and / or prevention of infertility, thereby improving the quality of oocytes and / or sperm.

[0189] In the implementation process of the present invention, attempts have been made to produce recombinant proteins comprising somatostatin antigenic determinants using spacers different from sequences 2 and 3. For example, attempts have been made to use the known spacer ProGlySerGlySerGlySerGlySerGlySerAla. These attempts, whether using a specific spacer in combination with one of the spacers of the present invention or using only a specific spacer, did not result in the formation of the correct three-dimensional structure of the recombinant protein, which eliminated the possibility of solving the problem. The technical results shown in this application accordingly failed to achieve the expected results, which shows the importance of optimizing the spacer selected for recombinant protein to solve the specified problem. Only the spacer developed according to the present invention leads to the formation of a U-shaped SSTad structure (which is identical to the somatostatin fragment between the two cysteines) and exposes the structure to the outside of the fusion protein. Thus, an immunodominant epitope is formed, thereby developing a preparation based on a recombinant protein that can induce a high immune response to somatostatin. In addition, as shown in the examples, the spacer of the present invention provides sufficient proteolytic protection for the antigenic determinant. All the effects of the present invention can only be achieved by using the spacer of the present invention.

[0190] Furthermore, in the course of implementing the present invention, the importance of precisely using two antigenic determinants was confirmed. However, since a single antigenic determinant has always been used in prior patents, the prior patents may not have suggested the use of two different somatostatin antigenic determinants. This technology is also new to the authors of the present invention relative to other immunogenic antigenic determinants, which demonstrates the originality and novelty of this approach. It should be emphasized that, in the course of studying the present invention, a recombinant protein having only one antigenic determinant was obtained. This recombinant protein did not exhibit the effects unique to the claimed invention. Similarly, the use of elements different from those used in the claimed invention does not successfully solve the problem to be solved.

[0191] To summarize the above facts, we can conclude that the main features of the present invention are the sequences of Spacer 1 and Spacer 2 of the present invention, and the use of two antigenic determinants having the sequence KNFFWKTFTS to obtain recombinant proteins for treating and / or preventing infertility and increasing folliculogenesis and spermatogenesis in mammals, birds and humans. Sequence Listing <110> UCI Pharmaceuticals Co., Ltd. <120> Recombinant GBD-SSTad-SSTad protein and its preparation method and use <130> 6626 / 0109PUS1 <140> US 17 / 435,358 <141> 2021-08-31 <150> PCT / EA2020 / 000003 <151> 2020-12-02 <150> RU 2019143669 <151> 2019-12-25 <160> 11 <170> PatentIn version 3.5 <210> 1 <211> 10 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Amino acid sequence of somatostatin antigenic determinant <400> 1 Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser 1 5 10 <210> 2 <211> twenty three <212> PRT <213> Artificial sequence <220> <223> synthetic <220> <221> misc_feature <223> Amino acid sequence of spacer 1 <400> 2 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10 15 Ala Gly Gly Gly Gly Ser Arg 20 <210> 3 <211> 85 <212> PRT <213> Artificial sequence <220> <223> synthetic <220> <221> misc_feature <223> Amino acid sequence of spacer 2 <400> 3 Ser Gly Thr Gly Ser Gly Glu Ile Ala Ala Leu Glu Gln Glu Ile Ala 1 5 10 15 Ala Leu Glu Lys Glu Asn Ala Ala Leu Glu Trp Glu Ile Ala Ala Leu 20 25 30 Glu Gln Gly Gly Pro Gly Thr Gly Gly Thr Gly Thr Gly Ser Gly Ala 35 40 45 Lys Ile Ala Ala Leu Lys Gln Lys Ile Ala Ala Leu Lys Tyr Lys Asn 50 55 60 Ala Ala Leu Lys Lys Lys Ile Ala Ala Leu Lys Gln Gly Gly Gly Thr 65 70 75 80 Gly Ser Gly Thr Arg 85 <210> 4 <211> 136 <212> PRT <213> Streptococcus mutans <220> <221> misc_feature <223> Amino acid sequence of the alpha-glucan binding domain of Streptococcus mutans <400> 4 Met Gly Ser Thr Asn Gln Tyr Tyr Gln Leu Ala Asp Gly Lys Tyr Met 1 5 10 15 Leu Leu Asp Asp Ser Gly Arg Ala Lys Thr Gly Phe Val Leu Gln Asp 20 25 30 Gly Val Leu Arg Tyr Phe Asp Gln Asn Gly Glu Gln Val Lys Asp Ala 35 40 45 Ile Ile Val Asp Pro Asp Thr Asn Leu Ser Tyr Tyr Phe Asn Ala Thr 50 55 60 Gln Gly Val Ala Val Lys Asn Asp Tyr Phe Glu Tyr Gln Gly Asn Trp 65 70 75 80 Tyr Leu Thr Asp Ala Asn Tyr Gln Leu Ile Lys Gly Phe Lys Ala Val 85 90 95 Asp Asp Ser Leu Gln His Phe Asp Glu Val Thr Gly Val Gln Thr Lys 100 105 110 Asp Ser Ala Leu Ile Ser Ala Gln Gly Lys Val Tyr Gln Phe Asp Asn 115 120 125 Asn Gly Asn Ala Val Ser Ala Arg 130 135 <210> 5 <211> 1250 <212> DNA <213> Artificial Sequence <220> <223> Synthetic: GBD-SSTad-SSTad <220> <221> CDS <222> (115)..(1164) <400> 5 ctcgagaaat cataaaaaat ttatttgctt tgtgagcgga taacaattat aatagattca 60 attgtgagcg gataacaatt tcacacagaa ttcattaag aggaaatt aact atg 117 Met 1 ggc tcc acc aat ca tat tat ca ctt gcc gat ggc aaa tat atg ctt 165 Gly Ser Thr Asn Gln Tyr Tyr Gln Leu Ala Asp Gly Lys Tyr Met Leu 5 10 15 ctt gat gat tcc gggc agg gcc aaa acc gtt gtt ctt caa gat ggc 213 Leu Asp Asp Ser Gly Arg Ala Lys Thr Gly Phe Val Leu Gln Asp Gly 20 25 30 gtt ctt agg tat tt gat caat gcc gaca ca gtt aaa gat gcc att 261 Val Leu Arg Tyr Phe Asp Gln Asn Gly Glu Gln Val Lys Asp Ala Ile 35 40 45 att gtt gat ccc gat acc aat ctt tcc tat tat ttt aat gcc acc caa 309 Ile Val Asp Pro Asp Thr Asn Leu Ser Tyr Tyr Phe Asn Ala Thr Gln 50 55 60 65 ggc gtt gcc gtt aaa at gat tat ttt gaa tat caa ggc aat tgg tat Gly Val Ala Val Lys Asn Asp Tyr Phe Glu Tyr Gln Gly Asn Trp Tyr 70 75 80 ctt acc gat gcc aat tat caa ctt att aaa ggc ttt aaa gcc gtt gat 405 Leu Thr Asp Ala Asn Tyr Gln Leu Ile Lys Gly Phe Lys Ala Val Asp 85 90 95 gat tcc ctt caa cat ttt gat gaa gtt acc ggc gtt caa acc aaa gat 453 Asp Ser Leu Gln His Phe Asp Glu Val Thr Gly Val Gln Thr Lys Asp 100 105 110 tcc gcc ctt att tcc gcc caa ggc aaa gtt tat caa ttt gat aat aat 501 Ser Ala Leu Ile Ser Ala Gln Gly Lys Val Tyr Gln Phe Asp Asn Asn 115 120 125 ggc aat gcc gtt tcc gcc agg tcc ggc ggc ggc ggc tcc ggc ggc ggc 549 Gly Asn Ala Val Ser Ala Arg Ser Gly Gly Gly Gly Ser Gly Gly Gly 130 135 140 145 ggc tcc ggc ggc ggc ggc tcc gcc ggc ggc ggc ggc tcc agg tcc ggc 597 Gly Ser Gly Gly Gly Gly Ser Ala Gly Gly Gly Gly Ser Arg Ser Gly 150 155 160 acc ggc tcc ggc gaa att gcc gcc ctt gaa caa gaa att gcc gcc ctt 645 Thr Gly Ser Gly Glu Ile Ala Ala Leu Glu Gln Glu Ile Ala Ala Leu 165 170 175 gaa aaa gaa aat gcc gcc ctt gaa tgg gaa att gcc gcc ctt gaa caa 693 Glu Lys Glu Asn Ala Ala Leu Glu Trp Glu Ile Ala Ala Leu Glu Gln 180 185 190 ggc ggc ccc ggc acc ggc aaa aat ttt ttt tgg aaa acc ttt acc tcc 741 Gly Gly Pro Gly Thr Gly Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser 195 200 205 ggc acc ggc acc ggc tcc ggc gcc aaa att gcc gcc ctt aaa caa aaa 789 Gly Thr Gly Thr Gly Ser Gly Ala Lys Ile Ala Ala Leu Lys Gln Lys 210 215 220 225 att gcc gcc ctt aaa tat aaa aat gcc gcc ctt aaa aaa aaa att gcc 837 Ile Ala Ala Leu Lys Tyr Lys Asn Ala Ala Leu Lys Lys Lys Ile Ala 230 235 240 gcc ctt aaa caa ggc ggc ggc acc ggc tcc ggc acc agg tcc ggc acc 885 Ala Leu Lys Gln Gly Gly Gly Thr Gly Ser Gly Thr Arg Ser Gly Thr 245 250 255 ggc tcc ggc gaa att gcc gcc ctt gaa caa gaa att gcc gcc ctt gaa 933 Gly Ser Gly Glu Ile Ala Ala Leu Glu Gln Glu Ile Ala Ala Leu Glu 260 265 270 aaa gaa aat gcc gcc ctt gaa tgg gaa att gcc gcc ctt gaa caa ggc 981 Lys Glu Asn Ala Ala Leu Glu Trp Glu Ile Ala Ala Leu Glu Gln Gly 275 280 285 ggc ccc ggc acc ggc aaa aat ttt ttt tgg aaa acc ttt acc tcc ggc 1029 Gly Pro Gly Thr Gly Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Gly 290 295 300 305 acc ggc acc ggc tcc ggc gcc aaa att gcc gcc ctt aaa caa aaa att 1077 Thr Gly Thr Gly Ser Gly Ala Lys Ile Ala Ala Leu Lys Gln Lys Ile 310 315 320 gcc gcc ctt aaa tat aaa aat gcc gcc ctt aaa aaa aaa att gcc gcc 1125 Ala Ala Leu Lys Tyr Lys Asn Ala Ala Leu Lys Lys Lys Ile Ala Ala 325 330 335 ctt aaa caa ggc ggc ggc acc ggc tcc ggc acc agg tcc taaccggact 1174 Leu Lys Gln Gly Gly Gly Thr Gly Ser Gly Thr Arg Ser 340 345 350 tcgaagcgtt cggttgggtc cggaatttcg tatggcaatg aaagacggtg agctggtgat 1234 atgggatagt gttcac 1250 <210> 6 <211> 350 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 6 Met Gly Ser Thr Asn Gln Tyr Tyr Gln Leu Ala Asp Gly Lys Tyr Met 1 5 10 15 Leu Leu Asp Asp Ser Gly Arg Ala Lys Thr Gly Phe Val Leu Gln Asp 20 25 30 Gly Val Leu Arg Tyr Phe Asp Gln Asn Gly Glu Gln Val Lys Asp Ala 35 40 45 Ile Ile Val Asp Pro Asp Thr Asn Leu Ser Tyr Tyr Phe Asn Ala Thr 50 55 60 Gln Gly Val Ala Val Lys Asn Asp Tyr Phe Glu Tyr Gln Gly Asn Trp 65 70 75 80 Tyr Leu Thr Asp Ala Asn Tyr Gln Leu Ile Lys Gly Phe Lys Ala Val 85 90 95 Asp Asp Ser Leu Gln His Phe Asp Glu Val Thr Gly Val Gln Thr Lys 100 105 110 Asp Ser Ala Leu Ile Ser Ala Gln Gly Lys Val Tyr Gln Phe Asp Asn 115 120 125 Asn Gly Asn Ala Val Ser Ala Arg Ser Gly Gly Gly Gly Ser Gly Gly 130 135 140 Gly Gly Ser Gly Gly Gly Gly Ser Ala Gly Gly Gly Gly Ser Arg Ser 145 150 155 160 Gly Thr Gly Ser Gly Glu Ile Ala Ala Leu Glu Gln Glu Ile Ala Ala 165 170 175 Leu Glu Lys Glu Asn Ala Ala Leu Glu Trp Glu Ile Ala Ala Leu Glu 180 185 190 Gln Gly Gly Pro Gly Thr Gly Lys Asn Phe Phe Trp Lys Thr Phe Thr 195 200 205 Ser Gly Thr Gly Thr Gly Ser Gly Ala Lys Ile Ala Ala Leu Lys Gln 210 215 220 Lys Ile Ala Ala Leu Lys Tyr Lys Asn Ala Ala Leu Lys Lys Lys Ile 225 230 235 240 Ala Ala Leu Lys Gln Gly Gly Gly Thr Gly Ser Gly Thr Arg Ser Gly 245 250 255 Thr Gly Ser Gly Glu Ile Ala Ala Leu Glu Gln Glu Ile Ala Ala Leu 260 265 270 Glu Lys Glu Asn Ala Ala Leu Glu Trp Glu Ile Ala Ala Leu Glu Gln 275 280 285 Gly Gly Pro Gly Thr Gly Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser 290 295 300 Gly Thr Gly Thr Gly Ser Gly Ala Lys Ile Ala Ala Leu Lys Gln Lys 305 310 315 320 Ile Ala Ala Leu Lys Tyr Lys Asn Ala Ala Leu Lys Lys Lys Ile Ala 325 330 335 Ala Leu Lys Gln Gly Gly Gly Thr Gly Ser Gly Thr Arg Ser 340 345 350 <210> 7 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 7 Asn Phe Phe Trp Lys Thr Phe Thr 1 5 <210> 8 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 8 Phe Phe Trp Lys Thr Phe 1 5 <210> 9 <211> 4 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 9 Phe Trp Lys Thr 1 <210> 10 <211> 12 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 10 Pro Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Ala 1 5 10 <210> 11 <211> 14 <212> PRT <213> Artificial sequence <220> <223> synthetic <400> 11 Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10

Claims

1. A recombinant GBD-SSTad-SSTad protein with a molecular weight of 39.5 kDa, wherein the recombinant protein is encoded by the GBD-SSTad-SSTad gene with a nucleotide sequence of SEQ ID NO:

5.

2. A method for preparing the recombinant GBD-SSTad-SSTad protein according to claim 1 on dextran, the method comprising: During the incubation process, GBD-SSTad-SSTad protein in the cell extract of Escherichia coli BL21 strain transformed with the pGBD-SSTad-SSTad plasmid was bound to the α-glycan-containing adsorbent based on affinity interaction, and the desired product was subsequently washed and separated from unbound bacterial proteins.

3. A pharmaceutical composition in the form of an injectable preparation for enhancing folliculogenesis and spermatogenesis in mammals, birds and humans, the composition comprising the recombinant GBD-SSTad-SSTad protein of claim 1 and an adjuvant suitable for injection.

4. The pharmaceutical composition of claim 3, wherein the composition is contained in one or more containers enclosed in a package with a leaflet containing instructions for use.

5. The pharmaceutical composition according to claim 3 or 4, wherein the pharmaceutical composition is a vaccine.

6. Use of recombinant GBD-SSTad-SSTad protein in the preparation of an injectable pharmaceutical composition for enhancing folliculogenesis and spermatogenesis in mammals, birds and humans, wherein the injection dose of the protein is 5-50 μg of the protein per kilogram of body weight of the mammal or bird.